Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress of the European Hematology Association, held from June 13 to 16 in Madrid.
Jeremy Abramson, M.D., from the Massachusetts General Hospital Cancer Center in Boston, and colleagues examined the efficacy and safety of Glofit-GemOx versus R-GemOx in patients with R/R DLBCL after one or more prior lines of therapy. A total of 274 patients were randomly assigned in a 2:1 ratio to receive Glofit-GemOx or R-GemOx (183 and 91 individuals, respectively).
The researchers observed a significant overall survival benefit with Glofit-GemOx versus R-GemOx at primary analysis (cutoff date, March 29, 2023). Median overall survival was not reached for Glofit-GemOx versus nine months for R-GemOx at a median follow-up of 11.3 months. Independent review committee-assessed progression-free survival and complete remission rate demonstrated a significant benefit for Glofit-GemOx. Glofit-GemOx continued to demonstrate superior median overall survival, median progression-free survival, and complete remission rates at follow-up analysis conducted once all patients had completed therapy (cutoff date, Feb. 16, 2024; median follow-up, 20.7 months) versus R-GemOx. Adverse event rates were higher with Glofit-Gemox than R-GemOx, including grade 3 to 4 and grade 5 adverse events and serious adverse events; however, the rates were similar after adjustment for exposure differences.
"Glofitamab in combination with GemOx showed clinically significant improvement in overall survival, as well as key secondary end points, and the benefits were reinforced with an additional 11 months of follow-up," Abramson said in a statement.
The study was funded by Genentech, the manufacturer of glofitamab.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Survival Improves With Open Hysterectomy for Cervical Cancer
FRIDAY, June 28, 2024 -- For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally invasive versus open radical...
Precision-Guided Treatment Improves Outcomes for High-Risk Pediatric Cancer
FRIDAY, June 28, 2024 -- Precision-guided treatment improves outcomes for children with high-risk cancer, according to a study published online June 6 in Nature Medicine. Loretta...
Recommendations Issued for Advanced Imaging for Pediatric Patients in ED
THURSDAY, June 27, 2024 -- In a policy statement issued by the American Academy of Pediatrics and published online June 27 in Pediatrics, recommendations are presented for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.